Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed consistent favourable, although non-significant, effects on carotid intima-media thickness (CIMT) progression at 48 weeks. We hereby communicate planned final 96 week results on biomarker changes and CIMT progression.
METHODS: PWH on a PI/r-based triple therapy regimen were randomly assigned (1:1) to switch the PI/r component to dolutegravir either immediately (DTG-I group) or after 48 weeks (DTG-D group) and were followed up to 96 weeks. We assessed changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin resistance, hypercoagulability, heart failure, myocardial injury and glomerular and tubular kidney injury, and right and left CIMT progression at 48 and 96 weeks.
RESULTS: Of 415 PWH randomized, 287 (69%) and 143 (34%) contributed to the biomarker and CIMT substudies respectively. There were significant 96 week changes in biomarkers associated with inflammation, immune activation, oxidation, insulin resistance and myocardial injury. Most changes were favourable, except for adiponectin reduction, which may suggest higher insulin resistance. We were unable to detect significant changes in the progression of CIMT between arms or within arms at 96 weeks.
DISCUSSION: After 96 weeks, switching from PI/r to dolutegravir in PWH with high cardiovascular risk led to significant changes in several biomarkers associated with cardiovascular disease. Although most changes were favourable, adiponectin reduction was not. There were non-significant changes in CIMT progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - 78(2023), 9 vom: 05. Sept., Seite 2361-2365 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
González-Cordón, Ana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adiponectin |
|---|
| Anmerkungen: |
Date Completed 06.09.2023 Date Revised 28.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jac/dkad247 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36039213X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36039213X | ||
| 003 | DE-627 | ||
| 005 | 20240229170217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dkad247 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM36039213X | ||
| 035 | |a (NLM)37539492 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a González-Cordón, Ana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2023 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed consistent favourable, although non-significant, effects on carotid intima-media thickness (CIMT) progression at 48 weeks. We hereby communicate planned final 96 week results on biomarker changes and CIMT progression | ||
| 520 | |a METHODS: PWH on a PI/r-based triple therapy regimen were randomly assigned (1:1) to switch the PI/r component to dolutegravir either immediately (DTG-I group) or after 48 weeks (DTG-D group) and were followed up to 96 weeks. We assessed changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin resistance, hypercoagulability, heart failure, myocardial injury and glomerular and tubular kidney injury, and right and left CIMT progression at 48 and 96 weeks | ||
| 520 | |a RESULTS: Of 415 PWH randomized, 287 (69%) and 143 (34%) contributed to the biomarker and CIMT substudies respectively. There were significant 96 week changes in biomarkers associated with inflammation, immune activation, oxidation, insulin resistance and myocardial injury. Most changes were favourable, except for adiponectin reduction, which may suggest higher insulin resistance. We were unable to detect significant changes in the progression of CIMT between arms or within arms at 96 weeks | ||
| 520 | |a DISCUSSION: After 96 weeks, switching from PI/r to dolutegravir in PWH with high cardiovascular risk led to significant changes in several biomarkers associated with cardiovascular disease. Although most changes were favourable, adiponectin reduction was not. There were non-significant changes in CIMT progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a dolutegravir |2 NLM | |
| 650 | 7 | |a DKO1W9H7M1 |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Adiponectin |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 700 | 1 | |a Assoumou, Lambert |e verfasserin |4 aut | |
| 700 | 1 | |a Moyle, Graeme |e verfasserin |4 aut | |
| 700 | 1 | |a Waters, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Domingo, Pere |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Stellbrink, Hans-Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Guaraldi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Masiá, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Gompels, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a De Wit, Stephane |e verfasserin |4 aut | |
| 700 | 1 | |a Florence, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Esser, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Raffi, François |e verfasserin |4 aut | |
| 700 | 1 | |a Behrens, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Pozniak, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Gatell, Jose M |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Esteban |e verfasserin |4 aut | |
| 700 | 0 | |a NEAT 022 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Vandekerckhove, Linos |e investigator |4 oth | |
| 700 | 1 | |a Caluwé, Els |e investigator |4 oth | |
| 700 | 1 | |a De Wit, Stephane |e investigator |4 oth | |
| 700 | 1 | |a Necsoi, Coca |e investigator |4 oth | |
| 700 | 1 | |a Florence, Eric |e investigator |4 oth | |
| 700 | 1 | |a Van Frankenhuijsen, Maartje |e investigator |4 oth | |
| 700 | 1 | |a Raffi, François |e investigator |4 oth | |
| 700 | 1 | |a Allavena, Clotilde |e investigator |4 oth | |
| 700 | 1 | |a Reliquet, Véronique |e investigator |4 oth | |
| 700 | 1 | |a Boutoille, David |e investigator |4 oth | |
| 700 | 1 | |a Cavellec, Morane |e investigator |4 oth | |
| 700 | 1 | |a André-Garnier, Elisabeth |e investigator |4 oth | |
| 700 | 1 | |a Rodallec, Audrey |e investigator |4 oth | |
| 700 | 1 | |a Le Tourneau, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Connault, Jérôme |e investigator |4 oth | |
| 700 | 1 | |a Molina, Jean-Michel |e investigator |4 oth | |
| 700 | 1 | |a Ferret, Samuel |e investigator |4 oth | |
| 700 | 1 | |a Previlon, Miresta |e investigator |4 oth | |
| 700 | 1 | |a Yazdanpanah, Yazdan |e investigator |4 oth | |
| 700 | 1 | |a Landman, Roland |e investigator |4 oth | |
| 700 | 1 | |a Joly, Véronique |e investigator |4 oth | |
| 700 | 1 | |a Pinto, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Katlama, Christine |e investigator |4 oth | |
| 700 | 1 | |a Caby, Fabienne |e investigator |4 oth | |
| 700 | 1 | |a Ktorza, Nadine |e investigator |4 oth | |
| 700 | 1 | |a Schneider, Luminita |e investigator |4 oth | |
| 700 | 1 | |a Stephan, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Wolf, Timo |e investigator |4 oth | |
| 700 | 1 | |a Schüttfort, Gundolf |e investigator |4 oth | |
| 700 | 1 | |a Rockstroh, Juergen |e investigator |4 oth | |
| 700 | 1 | |a Wasmuth, Jan-Christian |e investigator |4 oth | |
| 700 | 1 | |a Schwarze-Zander, Carolynne |e investigator |4 oth | |
| 700 | 1 | |a Boesecke, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Stellbrink, Hans-Jurgen |e investigator |4 oth | |
| 700 | 1 | |a Hoffmann, Christian |e investigator |4 oth | |
| 700 | 1 | |a Sabranski, Michael |e investigator |4 oth | |
| 700 | 1 | |a Esser, Stephan |e investigator |4 oth | |
| 700 | 1 | |a Jablonka, Robert |e investigator |4 oth | |
| 700 | 1 | |a Wiehler, Heidi |e investigator |4 oth | |
| 700 | 1 | |a Behrens, Georg |e investigator |4 oth | |
| 700 | 1 | |a Stoll, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Ahrenstorf, Gerrit |e investigator |4 oth | |
| 700 | 1 | |a Guaraldi, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Nardini, Giulia |e investigator |4 oth | |
| 700 | 1 | |a Beghetto, Barbara |e investigator |4 oth | |
| 700 | 1 | |a D'Arminio Montforte, Antonella |e investigator |4 oth | |
| 700 | 1 | |a Bini, Teresa |e investigator |4 oth | |
| 700 | 1 | |a Cogliandro, Viola |e investigator |4 oth | |
| 700 | 1 | |a Di Pietro, Massimo |e investigator |4 oth | |
| 700 | 1 | |a Fusco, Francesco Maria |e investigator |4 oth | |
| 700 | 1 | |a Galli, Massimo |e investigator |4 oth | |
| 700 | 1 | |a Rusconi, Stefano |e investigator |4 oth | |
| 700 | 1 | |a Giacomelli, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Meraviglia, Paola |e investigator |4 oth | |
| 700 | 1 | |a Martinez, Esteban |e investigator |4 oth | |
| 700 | 1 | |a González-Cordón, Ana |e investigator |4 oth | |
| 700 | 1 | |a Gatell, José Maria |e investigator |4 oth | |
| 700 | 1 | |a Torres, Berta |e investigator |4 oth | |
| 700 | 1 | |a Domingo, Pere |e investigator |4 oth | |
| 700 | 1 | |a Mateo, Gracia |e investigator |4 oth | |
| 700 | 1 | |a Gutierrez, Mar |e investigator |4 oth | |
| 700 | 1 | |a Portilla, Joaquin |e investigator |4 oth | |
| 700 | 1 | |a Merino, Esperanza |e investigator |4 oth | |
| 700 | 1 | |a Reus, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Boix, Vicente |e investigator |4 oth | |
| 700 | 1 | |a Masia, Mar |e investigator |4 oth | |
| 700 | 1 | |a Gutiérrez, Félix |e investigator |4 oth | |
| 700 | 1 | |a Padilla, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Clotet, Bonaventura |e investigator |4 oth | |
| 700 | 1 | |a Negredo, Eugenia |e investigator |4 oth | |
| 700 | 1 | |a Bonjoch, Anna |e investigator |4 oth | |
| 700 | 1 | |a Casado, José L |e investigator |4 oth | |
| 700 | 1 | |a Bañón-Escandell, Sara |e investigator |4 oth | |
| 700 | 1 | |a Saban, Jose |e investigator |4 oth | |
| 700 | 1 | |a Duque, Africa |e investigator |4 oth | |
| 700 | 1 | |a Podzamczer, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Saumoy, Maria |e investigator |4 oth | |
| 700 | 1 | |a Acerete, Laura |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez-Garcia, Juan |e investigator |4 oth | |
| 700 | 1 | |a Bernardino, José Ignacio |e investigator |4 oth | |
| 700 | 1 | |a Arribas, José Ramón |e investigator |4 oth | |
| 700 | 1 | |a Hontañón, Victor |e investigator |4 oth | |
| 700 | 1 | |a Moyle, Graeme |e investigator |4 oth | |
| 700 | 1 | |a Pagani, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Bracchi, Margherita |e investigator |4 oth | |
| 700 | 1 | |a Vera, Jaime |e investigator |4 oth | |
| 700 | 1 | |a Clarke, Amanda |e investigator |4 oth | |
| 700 | 1 | |a Adams, Tanya |e investigator |4 oth | |
| 700 | 1 | |a Richardson, Celia |e investigator |4 oth | |
| 700 | 1 | |a Winston, Alan |e investigator |4 oth | |
| 700 | 1 | |a Mora-Peris, Borja |e investigator |4 oth | |
| 700 | 1 | |a Mullaney, Scott |e investigator |4 oth | |
| 700 | 1 | |a Waters, Laura |e investigator |4 oth | |
| 700 | 1 | |a de Esteban, Nahum |e investigator |4 oth | |
| 700 | 1 | |a Milinkovic, Ana |e investigator |4 oth | |
| 700 | 1 | |a Pett, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Fox, Julie |e investigator |4 oth | |
| 700 | 1 | |a Tiraboschi, Juan Manuel |e investigator |4 oth | |
| 700 | 1 | |a Johnson, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Youle, Mike |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 78(2023), 9 vom: 05. Sept., Seite 2361-2365 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:9 |g day:05 |g month:09 |g pages:2361-2365 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkad247 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 9 |b 05 |c 09 |h 2361-2365 | ||